Dovramilast

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Dovramilast (CC-11050) 是一种磷酸二酯酶 4 (PDE4) 抑制剂，具有口服活性，可以减少炎症反应，改善 Isoniazid (HY-B0329) 介导的肺部细菌清除。Dovramilast 作为辅助试剂，可用于结核病的研究。

Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).

——

Dovramilast (oral gavage, 5, 25, or 50 mg/kg, single) significantly improves antibiotic-mediated bacterial killing and reduces lung pathology. Pharmacokinetic Parameters of Dovramilast in B6D2F1 mice.Animal Model:B6D2F1 mice Dosage:5, 25, or 50 mg/kg Administration:oral, 5, 25, or 50 mg/kg, single Result:Reduced PDE4 expression in mtb-infected mouse lungs.Animal Model:B6D2F1 mice Dosage:5, 25, or 50 mg/kg Administration:oral gavage, 5, 25, or 50 mg/kg, single Result:Improved antibiotic-mediated bacterial killing and reduced lung pathology.

——

Angiogenesis

PDE

PDE

——

——

340019-69-4

472.55

C24H28N2O6S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 25 mg/mL (52.90 mM; 超声助溶 (<60°C)

CCOc1cc(ccc1OC)[C@@H](CS(C)(=O)=O)N1Cc2cccc(NC(=O)C3CC3)c2C1=O

——

(-20℃)

With Ice Pack

≥ 2 years